DTx Pharma develops novel RNA-based therapeutics using a proprietary delivery platform that employs fatty acids as targeting ligands to enable oligonucleotide delivery to tissues and cell types throughout the body. Its FALCON fatty acid motifs are intended to improve cellular uptake and targeting of oligonucleotide therapies. In preclinical studies the company has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. Led by CEO Arthur T. Suckow, Ph.D., and COO Denise Bevers, the company plans to advance assets into clinical development across several therapeutic areas over the next few years. The company is based in San Diego, CA. DTx Pharma is developing a fatty-acid–mediated platform to deliver siRNA and other RNA-based treatments into cells. The company’s approach uses fatty acids to exploit cell membrane receptors and carry genetic material into cells like a Trojan horse. Founded in 2017 by Arthur Suckow with former Regulus colleagues John Grundy and Adam Pavlicek, the team aims to address the major delivery hurdle for RNA medicines. CEO and CSO Arthur Suckow leads technology development; Jeffrey Friedman joined as chief operating officer after investing through Tech Coast Angels. The company plans to use recent funds to develop a treatment for retinitis pigmentosa and to explore applications in muscular dystrophy. DTx is headquartered in Torrey Pines, has five local employees, and has demonstrated progress from cell culture to mouse studies per investor statements. Financially, it has raised $5.5 million to date and has also received two NIH Small Business Innovation Research grants of more than $300,000 each.

Total raised

$103M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2021